These data indicate that the changes in CPSF1 levels that occur in clinical prostate cancers during disease progression are likely to manifest as gene expression changes in the same genes that we identified in prostate cancer cell lines subjected to CPSF1 knockdown, including genes in the HALLMARK_GLYCOLYSIS gene set. The gene discussed is CPSF1; the disease is prostate carcinoma.